P-2 (P 2)

1.	Pajon, Eduardo R: 2 articles (06/2006 - 06/2006)
2.	Ganz, Patricia A: 2 articles (06/2006 - 06/2006)
3.	Costantino, Joseph P: 2 articles (06/2006 - 06/2006)
4.	Wickerham, D Lawrence: 2 articles (06/2006 - 06/2006)
5.	Wolmark, Norman: 2 articles (06/2006 - 06/2006)
6.	Wade, James L: 2 articles (06/2006 - 06/2006)
7.	Vogel, Victor G: 2 articles (06/2006 - 06/2006)
8.	Read, Jennifer S: 1 article (12/2007)
9.	Thompson, Bruce: 1 article (12/2007)
10.	Chen, Jian: 1 article (12/2007)

Related Diseases

1.	Neoplasms (Cancer) 07/01/2009 - "Analysis by primary tumor stage demonstrated that survival for T1-T3 disease was independent of treatment modality (P = .2); however, for T4 patients, operative treatment was associated with significantly better survival (55%) than CR (25%) or XRT (0%) (P < .0001). " 03/01/2009 - "Among the malignant tumors, the combined expression of BUB1B and PINK1 was the best predictor of overall survival (P < 2 x 10(-6)), and remained significant after adjusting for MacFarlane staging (P < .005). " 11/01/2007 - "In the control group, the percentage of cells incorporating BduR in the normal mucosa was 1.26% +/- 1.1% at endoscopy and 0.41% +/- 0.3% at surgery (p = .2), whereas the percentage of cells incorporating BduR in the tumor tissue was 1.41% +/- 1.2% at endoscopy and 0.48% +/- 0.6% at surgery (p = .2). " 11/01/2007 - "RESULTS: In the PN group, the mean percentage of tumor cells incorporating BduR was 2.51% +/- 1.7% in the endoscopic samples and 1.52% +/- 0.8% in the operative specimens (p = .2). " 08/01/2006 - "The pCR (n = 60) and control (n = 140) groups were similar in age (P = .6), sex (P = .4), distance of the tumor from the anal verge (P = .3), pre-CMT ERUS stage (P = .2), and comorbidities (P = .2). " Order ALL the reference details at left...
2.	Hypertension (High Blood Pressure) 06/01/2009 - "Hypertension control remained similar (P = .2) in both groups with cure/improvement in BP in 74% of PR and 89% of OR patients at one year. " 03/01/2009 - "In 29,717 individuals, the alleles of rs5068 and rs198358 that showed association with increased circulating natriuretic peptide concentrations were also found to be associated with lower systolic (P = 2 x 10(-6) and 6 x 10(-5), respectively) and diastolic blood pressure (P = 1 x 10(-6) and 5 x 10(-5)), as well as reduced odds of hypertension (OR = 0.85, 95% CI = 0.79-0.92, P = 4 x 10(-5); OR = 0.90, 95% CI = 0.85-0.95, P = 2 x 10(-4), respectively). " 01/01/2009 - "The major allele (A) of rs765250, located in intron 1, demonstrated the strongest evidence for association with SBP, effect size 3.14 mmHg (95%CI:1.23-4.9), DBP 1.9 mmHg (95%CI:0.7-3.2) and hypertension, odds ratio (OR: 1.3 [95%CI: 1.0-1.7]).We genotyped this variant in six independent populations (n = 14,451) and replicated the association between rs765250 and SBP in a meta-analysis (p = 7 x 10(-3), combined with BRIGHT data-set p = 2 x 10(-4), n = 17,851). " 06/01/1998 - "However, the age of onset of hypertension of patients with the DD genotype was lower (p < 20.05) and their left ventricular mass index was higher (p < 2 0.05) than those in patients with the non-DD genotype. " 09/01/1988 - "The absolute bioavailability and dose proportionality of betaxolol [(+/-)-1-(p-[2-cyclopropylmethoxy)ethyl]phenoxy]-3- (isopropylamino)-2-propanol hydrochloride], a cardioselective beta-adrenergic antagonist effective in the treatment of angina and hypertension, was studied in 12 healthy male subjects using a four-way crossover Latin Square design. " Order ALL the reference details at left...
3.	Infection 07/01/2008 - "LBP concentrations on admission and during the first week were similar in patients with gram-positive and those with gram-negative infections (15.9 [11-26.7] and 37.2 [25.1-62.4] vs. 16.3 [5.3-31.6] and 31.6 [13.4], microg/mL, p > .2). " 02/15/2007 - "At day 30, there was a trend for close contacts of CA-MRSA-infected patients to develop a similar infection (13% vs. 4%; odds ratio, 3.3; 95% confidence interval, 0.7-15.8; P=.2). " 08/15/2006 - "The rate of infection was 18% per cycle in older patients and 15% per cycle in younger patients (P = .2), with no difference noted in severity. " 07/01/2006 - "In addition, the 100-day and 3-year incidences of infection-related mortality (IRM) did not differ between groups (P = .2 and .5, respectively). " 08/15/2004 - "There was no difference in duration of parenteral antibiotic therapy (weighted mean difference, -4.3; 95% CI, -10.6 to 2.0 days; P =.2) or infection-related mortality (rate ratio, 1.02; 95% CI, 0.34 to 3.06; P =.97). " Order ALL the reference details at left...
4.	Neoplasm Metastasis (Metastasis) 04/02/1997 - "In contrast to the highly significant reduction in liver metastases seen in the initial study (79% reduction; SD = 15%; P = .00000007), the reduction found in the nine hypothesis-testing trials was not significant (14% reduction; SD = 10%; P = .2). " 05/01/2008 - "At univariate analysis, all variables were significantly correlated with recurrence (P = .001) except gender (P = .3); moreover, gender (P = .2), node dissection (P = .5), and node metastases (P = .06) were not significant on 10- and 15-year survival. " 05/01/2003 - "Similarly, the sTG level of the patients with nodal metastases increased between weeks 2 and 16 after the first vaccine treatment; by week 24, it had returned to pretreatment level in patients who survived more than 56 weeks but remained significantly elevated (p(2) < 0.01) in patients who survived less than 56 weeks. " 12/01/1998 - "There were no significant differences in CSM or distant metastasis rates between UL and BLR (P > .2). " 01/01/2009 - "The overall mortality rate (28 vs. 25, p = 0.36), the cancer-related death rate (17 vs. 19, p = .2), the local recurrence rate (7 vs. 12, p = .16), the distant metastasis rate (13 vs. 18, p = 0.2) as well as the time to relapse were not statistically significant different. " Order ALL the reference details at left...
5.	Anemia 01/01/1993 - "Stepwise discriminant analysis identified four variables (delayed onset of TSS symptoms after precipitating injury or event, more frequent CNS manifestations, less frequent musculoskeletal involvement, and higher degree of anemia) differentiating NMTSS patients from MTSS produced TSS toxin 1 (TSST-1) with comparable frequency (62% vs. 84%; P = .2), but production of staphylococcal enterotoxin A (SEA) was less common in NMTSS than in MTSS (33% vs. 74%; P = .01). " 02/15/2008 - "Using population- and family-based tests, we demonstrated that alleles producing functional ABO enzymes are associated with greater risk of severe malaria phenotypes (particularly malarial anemia) in comparison with the frameshift deletion underlying blood group O: case-control allelic odds ratio (OR), 1.2; 95% confidence interval (CI), 1.09-1.32; P = 0.0003; family-studies allelic OR, 1.19; 95% CI, 1.08-1.32; P = 0.001; pooled across all studies allelic OR, 1.18; 95% CI, 1.11-1.26; P = 2 x 10(-7). " 01/25/2005 - "We observed following grade 3 toxicities: asthenia (10%), neuropathy (4%), anorexia (4%), anemia (4%), hypersensitivity to P (2%), nausea/vomiting (2%), diarrhea (2%) and neutropenia (2%). " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Adenosine-5'-(N-ethylcarboxamide) (NECA)
2.	Adenosine
3.	Antigens
4.	Haloperidol (Haldol)
5.	Cisplatin (Platino)
6.	istradefylline
7.	E-Selectin
8.	Adrenergic Antagonists (Antiadrenergic Agents)
9.	Betaxolol (Kerlon)
10.	Scopolamine (Hyoscine)

Related Therapies and Procedures

1.	Bone Marrow Transplantation (Transplantation, Bone Marrow)
2.	Hysterectomy
3.	Dilatation and Curettage (D&C)
4.	Transplants (Transplant)
5.	Lasers (Laser)

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 20112 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>